Maharashtra FDA bans Cadila drugs

The India — Maharashtra Food and Drug Administration (FDA) has barred the sale and distribution of certain medicines manufactured by Cadila Pharmaceuticals Ltd, citing concerns over deceptive branding that could lead to medication errors. The regulator seized stock worth approximately INR 2.45 crore and ordered a recall of Aciloc 150, Aciloc 150 Plus, Aciloc 300, and Aciloc 300 Plus. The FDA found that the company marketed newer variants (Aciloc 150 Plus and Aciloc 300 Plus) containing Famotidine under nearly identical branding to older Ranitidine-based products, creating risk of confusion among doctors, pharmacists, and patients. FDA Commissioner Tukaram Mundhe emphasized the public health concern and stated that compliance with branding regulations is paramount. Further investigation and legal action under the Drugs and Cosmetics Act, 1940 are underway.